赢创利润同比增24%

Evonik profits up 24% YoY

中化新网讯 近日，赢创宣布，该公司2026年第二季度业绩表现强劲，与公司6月26日公布的初步数据一致。

China Chemical Industry News recently announced that the company's performance in the second quarter of 2026 was strong, consistent with the company's preliminary data released on June 26.

2026年第二季度，赢创调整后息税折旧摊销前利润(EBITDA)同比增长24%，达6.3亿欧元。今年6月，公司曾预计第二季度调整后EBITDA为6亿至6.5亿欧元，同时大幅上调2026全年业绩展望。目前，赢创预计全年调整后EBITDA将在20亿至22亿欧元之间。2025年，赢创调整后EBITDA约为19亿欧元。

In the second quarter of 2026, Evonik's adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) increased by 24% year-on-year to 630 million euros. In June of this year, the company had expected the adjusted EBITDA in the second quarter to hit 600 million to 650 million euros. It also sharply upgraded its full-year performance outlook for 2026. At present, Evonik expects its full-year adjusted EBITDA to be between 2 billion and 2.2 billion euros. In 2025, Evonik's adjusted EBITDA was about 1.9 billion euros.

赢创第二季度销售额同比增长11%，销量和销售价格均提升7%。净收益为8400万欧元。第二季度自由现金流为4900万欧元。

Evonik's sales in the second quarter increased by 11% year-on-year, and both sales volume and sales price increased by 7%. Net revenue were 84 million euros. Free cash flow in the second quarter was 49 million euros.

据介绍，赢创受益于全球供应链瓶颈带来的市场机遇，先进技术业务板块尤为如此。动物营养业务继续保持良好势头。

As reported, Evonik has benefited from market opportunities arising from global supply chain bottlenecks, especially its Advanced Technology Business segment. The animal nutrition business continued to maintain good momentum.